TABLE 2.
Safety analysis of infused patients
| Safety profile of infused patients | N = 75 |
|---|---|
| CRS | |
| Any grade; n (%) | 53 (71) |
| Grade ≥2; n (%) | 21 (28) |
| Grade ≥3; n (%) | 4 (5) |
| Time from infusion to start of CRS; median days (IQR) | 2 (1–4) |
| Duration CRS; median days (IQR) | 4 (4–6) |
| ICANS | |
| Any grade; n (%) | 11 (15) |
| Grade ≥2; n (%) | 6 (8) |
| Grade ≥3; n (%) | 1 (1) |
| Time from infusion to start of ICANS; median days (IQR) | 7 (5–9) |
| Duration ICANS; median days (IQR) | 9 (3–14) |
| ICU, n (%) | 10 (13) |
| Tocilizumab | |
| Patients; n (%) | 24 (32) |
| Median number doses tocilizumab (IQR) | 1 (1–5) |
| Corticosteroids | |
| Patients; n (%) | 16 (21) |
| Duration steroids; median days (IQR) | 11 (8–15) |
| Macrophage activation syndrome, n (%) | 3 (4) |
| Infections in the first month after infusion | |
| Patients, n (%) | 21 (28) |
| Infectious events | 31 |
| Bacterial | 19 |
| Viral | 8 |
| Fungal | 3 |
| Not identified | 1 |
| Tumor Lysis Syndrome, n (%) | 2 (3) |
| Treatment‐related mortality, n (%) | 3 (4) |
Abbreviations: Cytokine Release Syndrome (CRS); Immune Effector Associated Neurotoxicity Syndrome (ICANS); Intensive Care Unit (ICU); Interquartile range (IQR).